Particle.news

Download on the App Store

rPRO-seq Breakthrough Paves Way for Clinical RNA Biomarker Development

Researchers plan to deploy rPRO-seq on patient samples to develop RNA biomarkers that track treatment responses in real time.

Image
Image

Overview

  • The method requires just 12 hours and 5,000 cells compared with conventional approaches that need millions of cells and days to generate results.
  • By mapping nascent RNA, rPRO-seq reveals active transcription dynamics and offers mechanistic insights beyond steady-state RNA profiling.
  • Application to neuronal differentiation models identified INTS11 as essential for activating genes that guard against neurodevelopmental disorders.
  • A follow-up study showed INTS11’s regulatory role emerges by day two of embryonic development, positioning the Integrator complex at transcription initiation and challenging existing models.
  • Researchers aim to apply rPRO-seq to tumor biopsies to uncover unstable RNA biomarkers undetectable by current methods and monitor therapy efficacy.